Blood test may predict which rectal cancer patients can skip surgery

NCT ID NCT05081024

First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 25 times

Summary

This study looks at whether a simple blood test can help doctors decide if rectal cancer patients can avoid surgery. Researchers will measure tiny bits of tumor DNA in the blood (ctDNA) before, during, and after standard treatment. The goal is to see if changes in ctDNA levels can show which patients have a complete response to treatment, allowing them to keep their organs. About 50 adults with stage II or III rectal cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fred Hutch

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • OHSU Knight Cancer Institute

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.